BioTuesdays

Tag - Debjit Chattopadhyay

Bicycle Therapeutics Logo
Markets

HCW starts Bicycle Therapeutics at buy; PT $25

H.C. Wainwright initiated coverage of Bicycle Therapeutics (NASDAQ:BCYC) with a “buy” rating and $25 price target. The stock finished at $14.66 on April 17. The company is focused on bicycles, which are synthetic, short...

April 20, 2020
Molecular Partners
Markets

HCW starts Molecular Partners at buy; PT CHF29

H.C. Wainwright initiated coverage of Swiss-based Molecular Partners (SWX:MOLN) with a “buy” rating and price target of CHF29. The stock closed at CHF17.54 on April 1. Molecular Partners is developing targeted therapies...

April 2, 2020
Mersana Therapeutics Logo
Markets

HCW ups Mersana Therapeutics PT to $12 from $7

H.C. Wainwright raised its price target for Mersana Therapeutics (NASDAQ:MRSN) to $12 from $7, saying the expected data flow, and available activity and safety profile bode well for the company’s XMT-1536 drug candidate...

January 21, 2020
Stoke Therapeutics
Markets

HCW starts Stoke Therapeutics at buy; PT $30

H.C. Wainwright launched coverage of Stoke Therapeutics (NASDAQ:STOK) with a “buy” rating and price target of $30. The stock closed at $22.86. Analyst Debjit Chattopadhyay writes that Stoke is advancing an antisense...

October 25, 2019
Hookipa Pharma
Markets

HCW starts Hookipa Pharma at buy; PT $15

H.C. Wainwright launched coverage of HOOKIPA Pharma (NASDAQ:HOOK) with a “buy” rating and $15 price target. The stock closed at $7.76 on Sept. 26. Hookipa is a developing therapies that leverage its proprietary family...

September 27, 2019
Markets

HCW starts Sangamo Therapeutics at buy; PT $16

H.C. Wainwright initiated coverage of Sangamo Therapeutics (NASDAQ:SGMO) with a “buy” rating and $16 price target. The stock closed at $11.02 on Aug. 23. Analyst Debjit Chattopadhyay writes that the prevailing view on...

August 26, 2019
Precision Biosciences
Markets

HCW starts Precision BioSciences at buy; PT $21

H.C. Wainwright initiated coverage of Precision BioSciences (NASDAQ:DTIL) with a “buy” rating and $21 price target. The stock closed at $13.76 on July 15. Precision is one of the early adopters of a potential paradigm...

July 16, 2019